The Oncologist
Overview
The Oncologist is a reputable peer-reviewed medical journal that focuses on all aspects of cancer research and treatment. It provides a platform for oncologists, researchers, and healthcare professionals to share their latest findings, clinical trials, and advancements in cancer care. With a multidisciplinary approach, the journal aims to improve patient outcomes and contribute to the global fight against cancer.
Details
Details
Abbr.
Oncologist
Publisher
Oxford University Press
Start
1996
End
Continuing
Frequency
Monthly, 2007-
p-ISSN
1083-7159
e-ISSN
1549-490X
Country
United Kingdom
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 823
189
SJR / Ranks: 1203
1991
CiteScore / Ranks: 1397
10.10
Recent Articles
1.
Li Y, Li C, Zhao X, Li Y, He F, Pan Z
Oncologist
. 2025 Mar;
30(3).
PMID: 40088185
Background: To evaluate the efficacy and safety of aumolertinib combined with pemetrexed and carboplatin as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)...
2.
Levi A, Blais E, Davelaar J, Ebia M, Minasyan A, Nikravesh N, et al.
Oncologist
. 2025 Mar;
30(3).
PMID: 40079530
Background: Previous research demonstrates longer survival for patients with lung-only metastatic pancreatic adenocarcinoma (mPDAC) compared to liver-only mPDAC. The objective of this study is to understand the survival differences, impact...
3.
Morales A, Benson G, Glavan S, Giuliano R, Dickson M
Oncologist
. 2025 Mar;
30(3).
PMID: 40079529
Background: Kaposi sarcoma (KS) is a vascular tumor caused by human herpesvirus 8, also known as Kaposi sarcoma herpesvirus. There are 4 distinct subtypes: classic, endemic, iatrogenic, and epidemic (HIV-associated)....
4.
Ho I, Chiang N, Lai J, Chang P, Chen S, Hung Y, et al.
Oncologist
. 2025 Mar;
30(3).
PMID: 40063612
Background: Neuroendocrine carcinoma (NEC) is an aggressive, poorly differentiated Grade 3 (G3) tumor with high nuclear and cellular atypia and Ki-67 indices over 20%. While most cases are lung NECs,...
5.
Wang J, Zhao S, Niu T, Chen J, Li H, Xiong H, et al.
Oncologist
. 2025 Mar;
30(3).
PMID: 40063611
Purposes: Evidence has demonstrated that monitoring of the variable, diversity, and joining gene segments (VDJ) rearrangement of immunoglobulin (Ig) gene in the circulating tumor DNA (ctDNA) is highly valuable in...
6.
Gray Z, Levonyak N, Jia L, Ahn R, Balani J, Wang J
Oncologist
. 2025 Mar;
30(3).
PMID: 40063610
Prostate and colorectal adenocarcinoma are among the most common primary cancer diagnoses in the United States, with 29% of new cancer diagnoses among adult men in 2024 expected to arise...
7.
Li Y, Cui R, Yu Y, Huang Y, Yan Y, Sun J, et al.
Oncologist
. 2025 Mar;
30(3).
PMID: 40063609
NK-large granular lymphocytic leukemia (NK-LGLL) is a rare chronic lymphoproliferative disorder and displays heterogeneity that remains insufficiently defined. CD56 plays a pivotal role in NK-cell maturation linked to cytotoxicity. However,...
8.
Trinh M, Bear L, Nahed B, Iliopoulos O
Oncologist
. 2025 Mar;
30(3).
PMID: 40063608
Increasing accessibility to genetic screening for cancer risk can lead to earlier surveillance and prevention, but with this comes the caveat of incidental identification of germline pathogenic gene variants. Here,...
9.
Altomare N, Li Y, Neill C, Hussain M, VanderWeele D
Oncologist
. 2025 Mar;
30(3).
PMID: 40063607
Checkpoint inhibitors targeting PD-1/PD-L1, such as pembrolizumab, can be effective in a small population of biomarker-selected patients with metastatic prostate cancer (mPC), as has been demonstrated by small case series....
10.
Lo C, Chang D, Lu Y, Wang M, Tsai L, Huang C, et al.
Oncologist
. 2025 Mar;
30(2).
PMID: 40042201
Background: The efficacy of adjuvant chemotherapy for T1N0M0 triple-negative breast cancer (TNBC) has not been clearly elucidated. Thus, we aimed to evaluate the efficacy of adjuvant chemotherapy for patients with...